Andrija S Grustam1, Johan L Severens2, Daniele De Massari3, Nasuh Buyukkaramikli2, Ron Koymans4, Hubertus J M Vrijhoef5. 1. Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Professional Health Solutions and Services Department, Philips Research Europe, Eindhoven, The Netherlands. Electronic address: grustam@eshpm.eur.nl. 2. Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. 3. Chronic Disease Management Department, Philips Research Europe, Eindhoven, The Netherlands. 4. Professional Health Solutions and Services Department, Philips Research Europe, Eindhoven, The Netherlands. 5. Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Department of Patient and Care, Maastricht UMC, Maastricht, The Netherlands; Department of Family Medicine and Chronic Care, Vrije Universiteit Brussels, Brussels, Belgium.
Abstract
OBJECTIVES: To assess the cost effectiveness of home telemonitoring (HTM) and nurse telephone support (NTS) compared with usual care (UC) in the management of patients with chronic heart failure, from a third-party payer's perspective. METHODS: We developed a Markov model with a 20-year time horizon to analyze the cost effectiveness using the original study (Trans-European Network-Home-Care Management System) and various data sources. A probabilistic sensitivity analysis was performed to assess the decision uncertainty in our model. RESULTS: In the original scenario (which concerned the cost inputs at the time of the original study), HTM and NTS interventions yielded a difference in quality-adjusted life-years (QALYs) gained compared with UC: 2.93 and 3.07, respectively, versus 1.91. An incremental net monetary benefit analysis showed €7,697 and €13,589 in HTM and NTS versus UC at a willingness-to-pay (WTP) threshold of €20,000, and €69,100 and €83,100 at a WTP threshold of €80,000, respectively. The incremental cost-effectiveness ratios were €12,479 for HTM versus UC and €8,270 for NTS versus UC. The current scenario (including telenurse cost inputs in NTS) yielded results that were slightly different from those for the original scenario, when comparing all New York Heart Association (NYHA) classes of severity. NTS dominated HTM, compared with UC, in all NYHA classes except NYHA IV. CONCLUSIONS: This modeling study demonstrated that HTM and NTS are viable solutions to support patients with chronic heart failure. NTS is cost-effective in comparison with UC at a WTP of €9000/QALY or higher. Like NTS, HTM improves the survival of patients in all NYHA classes and is cost-effective in comparison with UC at a WTP of €14,000/QALY or higher.
OBJECTIVES: To assess the cost effectiveness of home telemonitoring (HTM) and nurse telephone support (NTS) compared with usual care (UC) in the management of patients with chronic heart failure, from a third-party payer's perspective. METHODS: We developed a Markov model with a 20-year time horizon to analyze the cost effectiveness using the original study (Trans-European Network-Home-Care Management System) and various data sources. A probabilistic sensitivity analysis was performed to assess the decision uncertainty in our model. RESULTS: In the original scenario (which concerned the cost inputs at the time of the original study), HTM and NTS interventions yielded a difference in quality-adjusted life-years (QALYs) gained compared with UC: 2.93 and 3.07, respectively, versus 1.91. An incremental net monetary benefit analysis showed €7,697 and €13,589 in HTM and NTS versus UC at a willingness-to-pay (WTP) threshold of €20,000, and €69,100 and €83,100 at a WTP threshold of €80,000, respectively. The incremental cost-effectiveness ratios were €12,479 for HTM versus UC and €8,270 for NTS versus UC. The current scenario (including telenurse cost inputs in NTS) yielded results that were slightly different from those for the original scenario, when comparing all New York Heart Association (NYHA) classes of severity. NTS dominated HTM, compared with UC, in all NYHA classes except NYHA IV. CONCLUSIONS: This modeling study demonstrated that HTM and NTS are viable solutions to support patients with chronic heart failure. NTS is cost-effective in comparison with UC at a WTP of €9000/QALY or higher. Like NTS, HTM improves the survival of patients in all NYHA classes and is cost-effective in comparison with UC at a WTP of €14,000/QALY or higher.
Authors: William V Padula; Marlea A Miano; Marcella A Kelley; Samuel A Crawford; Bryson H Choy; Robert M Hughes; Riley Grosso; Peter J Pronovost Journal: Value Health Date: 2021-10-23 Impact factor: 5.101
Authors: Gian Luca Di Tanna; Michael Urbich; Heidi S Wirtz; Barbara Potrata; Marieke Heisen; Craig Bennison; John Brazier; Gary Globe Journal: Pharmacoeconomics Date: 2020-11-30 Impact factor: 4.981
Authors: Sandra Sülz; Hilco J van Elten; Marjan Askari; Anne Marie Weggelaar-Jansen; Robbert Huijsman Journal: J Med Internet Res Date: 2021-03-09 Impact factor: 5.428
Authors: John A Batsis; Auden C McClure; Aaron B Weintraub; David F Kotz; Sivan Rotenberg; Summer B Cook; Diane Gilbert-Diamond; Kevin Curtis; Courtney J Stevens; Diane Sette; Richard I Rothstein Journal: Obes Sci Pract Date: 2019-10-17
Authors: Chris Boodoo; Qi Zhang; Heather J Ross; Ana Carolina Alba; Audrey Laporte; Emily Seto Journal: J Med Internet Res Date: 2020-10-06 Impact factor: 5.428